| dc.description.abstract | Non-alcoholic fatty liver (NAFLD) is one of the most common chronic metabolic
diseases in the world. The prevalence of obesity, type 2 diabetes, and insulin
resistance is closely linked to NAFLD. There is some evidence for the beneficial
effects of chromium picolinate in NAFLD. Its beneficial effects have been shown
to improve insulin sensitivity, reduce blood lipids and improve antioxidant status
in laboratory and animal studies. Therefore, due to the lack of human studies in
this case, the present study was designed and conducted to determine the effect of
oral administration of chromium picolinate on on Liver Function, Oxidative
Index, Leptin and Resistin in Non-Alcoholic Fatty Liver DiseaseMethods:
In this double-blind randomized clinical trial, 46 patients with NAFLD were
randomly assigned to receive 400 micrograms of chromium picolinate (in the
form of two 200-pound chromium picolinate pills) and placebo (taking two
placebo pills containing corn starch of similar weight and shape). Chromium
picolinate tablets were administered for 12 weeks. Measurement indicators
including weight, height and waist circumference (WC) and anthropometry
including fat mass, lean mass and total body water were measured, and
information on food intake and physical activity levels at the beginning and end of
the study was. Data on dietary intake and physical activity level of the subjectswere assessed at
the beginning and end of the study using 24 hour food intake and
short form of international physical activity Questionnaire respectively. Blood
pressure was also measured at the beginning and end of the study. Participant
intravenous blood sample after fasting 14-12 hours for determination of whole
blood glutathione peroxidase (GPX) levels, red blood cell superoxide dismutase
(SOD) and then serum isolation and storage to determine serum leptin, resistin,
malondialdehyde (MDA) serum levels. Alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and alkaline phosphatase (ALP) were taken from patients
at the beginning and end of the study.
Results:
Of total 46 patients enrolled, 43 subjects completed the study (22 in the
chromium picolinate group and 21 in the placebo group). Supplementation with
chromium picolinate compared with the placebo group caused a significant
increase in SOD (p = 0.037) enzyme activity and a significant decrease in serum
MDA (p = 0.015) and serum leptin (p = 0.011) as well as a decrease. Weight (p =
0.037) and body fat mass compared to the placebo group. However, it had no
effect on serum concentrations, resin, liver enzymes, antioxidant activity of GPX
enzyme red blood cells and other components of blood pressure and blood
pressure (p≥0.05). However, in the chromium picolinate group, after 12 weeks of
supplementation, a significant decrease in liver enzymes was observed compared
to the beginning of the study.
Conclusion:
The findings of our study suggested that the administration of chromium
picolinate (400 μg / day) for 12 weeks in patients with NAFLD has beneficialeffects on the oxidative stress, some anthropometric indices and leptin, but had no
effect on liver enzymes | en_US |
